Pharmaceutical companies still
see riches in biotechnology. AstraZeneca's $15.6 billion deal to acquire MedImmune
is only the latest example of their continuing willingness to pay high premiums
(in this case, a 53% premium to where MedImmune was trading before it put itself
up for sale) for future growth.